

Date: 28 May 2025

To

The Secretary BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400 001 Scrip Code: 544293	The Secretary National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1. G Block Bandra -Kurla Complex, Bandra (East) Mumbai- 400 051 Scrip Symbol : SURAKSHA
---	--

Dear Sir / Ma'am,

Reg: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

Sub: Press release in respect of audited (standalone and consolidated) financial results of the Company for quarter and financial year ended 31 March 2025

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed herewith the press release in relation to the audited (standalone and consolidated) financial results of the Company for quarter and financial year ended 31 March 2025.

Further, details as required to be disclosed as per BSE's Circular No. 20230714-34 dated 14 July 2023, and NSE's Circular No. NSE/CML/2023/57 dated 14 July 2023, are as under:

Date of occurrence of Event/Information: 28 May 2025

Time of occurrence of Event/Information: 11:10 pm

This may please be informed to all the concerned.

For **Suraksha Diagnostic Limited**

Mamta Jain

Company Secretary & Compliance Officer

Encl: As above

Suraksha Diagnostic Limited

CIN: L85110WB2005PLC102265

Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town

Kolkata-700 156, West Bengal, India

E-mail: investors@surakshanet.com | **Website:** www.surakshanet.com

Phone:(033) 6605 9750

Robust Top-line Growth in FY25

***FY25 Total Income increased by 15% year-on-year;
FY25 EBITDA grew by 16% with margins of 34%***

Kolkata, 28 May 2025: Suraksha Diagnostic Limited, the largest integrated diagnostic chain in East India, announced its audited financial results for the quarter and year ended 31 March 2025.

FY25 Financial Performance Snapshot (Y-o-Y)



Key Financial Highlights

Particulars (₹ million)	Q4 FY25	Q4 FY24	Y-o-Y	Q3 FY25	Q-o-Q	FY25	FY24	Y-o-Y
Total Income	659.1	561.7	17.4%	601.1	9.7%	2559.4	2222.6	15.2%
EBTIDA	200.1	204.5	-2.2%	188.6	6.1%	850.9	736.2	15.6%
EBTIDA Margin (%)	30.7%	37.1%		31.7%		33.8%	33.7%	
PAT	71.7	63.2	13.4%	59.9	19.8%	309.8	231.3	34.0%
PAT Margin (%)	11.0%	11.5%		10.1%		12.3%	10.6%	

Highlights:**Revenue from Operations:**

- For Q4 FY25, the company reported revenue from operations of ₹ 651.0 million, reflecting a growth of 18.0% compared to the same quarter last year.
- For the year ended FY25, revenue amounted to ₹ 2,520.9 million, a growth of 15.3 % year-on-year.

EBITDA:

- EBITDA for Q4 FY25 reached ₹ 200.1 million compared to ₹ 204.5 million in the previous year. The EBITDA margin for Q4 FY25 stood at 30.7%.
- For FY25, EBITDA totaled ₹ 850.9 million, a growth of 15.6% year-on-year. The EBITDA margin for FY25 stood at 33.8%, up from 33.7% in the corresponding period.

Profit After Tax (PAT):

- PAT for Q4 FY25 stood at ₹ 71.7 million, reflecting a growth of 13.4% year-on-year. The PAT margin for Q4 FY25 was 11.0%, compared to 11.5% in the same quarter last year.
- For FY25, PAT reached ₹ 309.8 million, an increase of 34.0 % year-on-year.

Other Highlights:

- During the quarter ended 31 March 2025, the Company entered into a Share Subscription Agreement to acquire 95,841 equity shares of ₹10/- each in Fetomat Wellness Private Limited ("Fetomat"), representing a 16.17% stake, at ₹ 100 lakhs. Subsequently, after 31 March 2025, the Company entered into Share Purchase Agreements with existing shareholders of Fetomat to acquire an additional 2,77,582 equity shares of ₹10/- each, increasing its total equity stake to approximately 63%, thereby obtaining control and making Fetomat a subsidiary of the Company.
- Added total of 7 Centers in the year with 1 big, 1 medium, 3 small centers and 2 PPP centers.

Commenting on the results Ms. Ritu Mittal, Joint Managing Director & CEO said, -

"We are pleased to present our first full-year financial results post-listing, marking a strong performance across FY25 with revenue growing by 15.3% year-on-year and PAT increasing by 34.0% year-on-year.

During the year, we added 7 centers, despite diversions such as the management's focus on the IPO, coupled with unfavorable events such as the doctors' strike and the Bangladesh issue. Looking ahead, we are optimistic about expansion, with approvals already in place for the majority of our planned centers. We anticipate adding 15-18 centers in FY26, supporting our long-term growth trajectory.

The acquisition of Fetomat Wellness Private Limited ('Fetomat') in April 2025, marked our entry into the field of genomic medicine. Fetomat operates in the healthcare segment with a focus on pregnancy care, women's ultrasound scanning, prenatal diagnostics, therapy, genetic counseling, and medical training for doctors. We believe this acquisition brings significant synergies with our existing operations and opens new avenues for sustainable growth.

We expect our EBITDA and PAT margins to improve further as we scale our operations and our centers reach maturity. With higher throughput, improved operating leverage and tighter cost controls, we expect meaningful margin expansion in our mature centers. As newer centers stabilize and start contributing significantly, we anticipate a stronger, more profitable financial profile across the network."

About Suraksha Diagnostic Limited:

Suraksha Diagnostic Limited is a leading provider of integrated solutions in pathology and radiology testing, as well as medical consultation services, offering a seamless experience to customers through an extensive operational network. The company is the largest integrated diagnostic chain with presence in the states of West Bengal, Bihar, Assam and Meghalaya.

The company's central reference laboratory is accredited by the College of American Pathologists, while the 4 laboratories hold National Accreditation Board for Testing and Calibration Laboratories (NABL) accreditation, and 3 advanced diagnostic centers are accredited by the National Accreditation Board for Hospitals & Healthcare Providers (NABH).

Company: Suraksha Diagnostic Limited	Investor Relations: MUFG Intime India Private Limited
Email: investors@surakshanet.com	Name: Mr. Ashish Tendulkar Email: ashish.tendulkar@in.mpms.mufg.com
CIN: L85110WB2005PLC102265	Name: Ms. Pooja Swami Email: pooja.swami@in.mpms.mufg.com
Website: https://www.surakshanet.com/	Meeting Request Link – Click Here

Safe Harbor

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of past performance also should not be simply extrapolated into the future. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downturn in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.